Market Signal Briefing

Scan QR code to install app

Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.Risk DisclaimersThis website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.

September 26, 2025 01:00 ET

 | Source:

Addex Therapeutics

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025.

Title:   Addex Therapeutics Reports Half-Year 2025 Financial Results and Provides Corporate Update
Date: October 1, 2025
Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) 

Joining the Conference Call:

Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.
Webcast registration URL:

https://edge.media-server.com/mmc/p/vh6nhzwt

Conference call registration URL:

https://register-conf.media-server.com/register/BI403a5726888046a6a0645698cc9fdaec

About Addex Therapeutics

Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com

  Contacts: 

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient population New data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settings Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025).

“We look forward to sharing new clinical data that underscores how we are reimagining treatment for breast and prostate cancer, advancing highly effective therapies designed to improve quality of life, enable more personalized care and ultimately provide more time for cancer patients,” said Dushen Chetty, PhD, Global Head of Oncology Development, Novartis, Ad Interim. “Our ambition is to set new standards of care in some of the most prevalent cancers by pioneering novel technologies like radioligand therapy.”

Key highlights of data accepted by ESMO include:

MedicineAbstract titleAbstract Number/
Presentation Details   Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan)Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)#LBA6
Presidential Symposium 2 (Proffered Paper session)
October 19, 2025
16:30 – 18:15 CESTPluvicto™ (lutetium (177Lu) vipivotide tetraxetan)Associations between quantitative baseline 68Ga-PSMA-11 PET parameters and 177Lu-PSMA-617 efficacy in the PSMAfore Study#2390P
Poster Presentation
October 18, 2025
09:00 – 17:00 CESTPluvicto™ (lutetium (177Lu) vipivotide tetraxetan)Final analysis of patients treated with [177Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France#2389P
Poster Presentation
October 18, 2025
09:00 – 17:00 CEST[225Ac]-PSMA-617PSMAcTION trial-in-progress: a phase 2/3 randomized trial of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) versus standard of care in patients with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA therapy#2516TiP
Poster Presentation
October 18, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes#LBA14
Proffered Paper session
October 17, 2025
14:00 – 15:30 CESTKisqali® (ribociclib)Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2− EBC: a subgroup analysis from the phase 3 NATALEE trial#366P
Poster Presentation
October 20, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)A NATALEE data–based machine learning (ML) model to predict distant recurrence (DR) and treatment (tx) effect in real-world (RW) patients (pts) with HR+/HER2– early breast cancer (EBC) without CDK4/6 inhibitor (CDK4/6i) tx#372P
Poster Presentation
October 20, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)Real-world characteristics, treatments and outcomes of NATALEE and monarchE-eligible HR+/HER2- early breast cancer patients in the hospital district of Helsinki and Uusimaa (HUS), Finland#360P
Poster Presentation
October 20, 2025
09:00 – 17:00 CESTKisqali® (ribociclib)Risk of Recurrence (ROR) After Neoadjuvant Ribociclib Plus ET in Clinically High-Risk ER+/HER2− BC: Preliminary Analysis of the SOLTI-RIBOLARIS Trial #296O
Proffered Paper session
October 17, 2025
14:00 – 15:30 CEST Novartis in oncology
The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients.

As Novartis reimagines medicine, it collaborates with a wide range of patient advocacy groups and supports education, early cancer screening and diagnosis. With approximately 35 research and development projects across solid tumors, hematology and radioligand therapy (RLT), Novartis is committed to using technology, leading science and patient-centered research to deliver pioneering cancer care for all those in need.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Novartis Media Relations
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

This transcription was created from a CEF Insights podcast recorded in September 2025. For more information, please visit cefa.com. This material is not and is not intended as investment advice, an indication of trading intent or holdings or the prediction of investment performance. All fund-specific information is the latest publicly available information. All other information is current as of the date of this presentation. All opinions and forward-looking statements are subject to change at any time.
Western Asset Management disclaims any responsibility to update such views and/or information. This information is deemed to be from reliable sources; however, Western Asset does not warrant its completeness or accuracy. This presentation is not intended to, and does not constitute an offer or solicitation to sell or a solicitation of an offer to buy any security, product, investment advice or service (nor shall any security, product, investment advice or service be offered or sold) in any jurisdiction in which Western Asset is not licensed to conduct business, and/or an offer, solicitation, purchase or a sale would be unavailable or unlawful.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryHubSpot remains a buy, driven by strong AI execution, rapid Core Seat adoption, and accelerating multi-hub usage.HUBS's AI strategy, including "The Loop" and Data Hub, positions customers for success in the evolving Agent Engine Optimization (AEO) landscape.The new seat-based pricing model increases user penetration and embeds HUBS deeper into organizations, fueling robust ARR growth. MoMo Productions/DigitalVision via Getty Images

Investment action I had a buy rating for HubSpot (NYSE:HUBS) previously, as I believed it was in a great position to grow robustly, with support from the shift to seat-based pricing and AI monetization. The latest updates, particularly from INBOUND 2025, reinforce my

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Crinetics Pharmaceuticals, Inc. - Special Call

Company Participants

Gayathri Diwakar - Senior Director of Investor Relations
R. Struthers - Founder, President, CEO & Director
Dana Pizzuti - Chief Medical & Development Officer
Isabel Kalofonos - Chief Commercial Officer
Tobin Schilke - Chief Financial Officer
Alan Krasner - Chief Endocrinologist

Conference Call Participants

Joshua Schimmer - Cantor Fitzgerald & Co., Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division
Joseph Schwartz - Leerink Partners LLC, Research Division
Anthea Li - Jefferies LLC, Research Division
Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
Cory Jubinville - LifeSci Capital, LLC, Research Division
Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division
Catherine Novack - JonesTrading Institutional Services, LLC, Research Division

Presentation

Operator

Welcome to the Crinetics Pharmaceuticals PALSONIFY FDA Approval Conference Call. [Operator Instructions]

I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead.

Gayathri Diwakar
Senior Director of Investor Relations

Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the FDA approval of PALSONIFY. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer; Dr. Dana Pizzuti, Chief Medical and Development Officer; and Isabel Kalofonos, Chief Commercial Officer. In addition, Tobin Schilke, Chief Financial Officer; and Dr. Alan Krasner, Chief Endocrinologist, will also be joining for the Q&A portion.

Please note, there is a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Crinetics website. In addition, a press release was issued earlier today and is also available on the corporate website.

Slide 2. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these

Recommended For You

September 26, 2025 02:00 ET

 | Source:

Norsk Hydro

Hydro's third quarter results 2025 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on October 24, 2025. The quarterly report and presentation will be available on hydro.com at the same time as the release.  

President and CEO Eivind Kallevik and Executive Vice President and CFO Trond Olaf Christophersen, will host a webinar in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no physical presentation or press conference.  

To join the webinar and ask questions, use the link to the webcast page.  

The webcast is powered by Zoom. No login or registration in advance is required. It is also possible to log in using the dial-in option:  

Norway +47 2400 4736 

London, UK +44 330 088 5830 

New York, US +1 929 205 6099 

Find your local number 

Meeting ID: 933 0129 2025

We advise you to investigate in advance if your company has any restrictions using the Zoom platform. 

Investor contact: 

Martine Rambøl Hagen 
+47 91708918 
[email protected] 

, /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced that its new used car superstore in Zhengzhou, Henan Province will officially open on September 27, 2025.

The Zhengzhou used car superstore has a gross floor area of approximately 150,000 square meters, integrating one of China's largest used-car showrooms with an in-house reconditioning facility. The site is designed to accommodate up to 5,000 vehicles for display and sale. Following the Company's successful launch of superstores in Xi'an, Hefei, and Wuhan, Zhengzhou marks Uxin's fourth superstore, underscoring the Company's ability to replicate and scale its business model across major Chinese cities.

Zhengzhou is the capital city of Henan Province, which is one of China's most populous provinces. The city has a resident population exceeding 13 million and over 5 million registered vehicles. Zhengzhou ranks among the top ten cities nationwide in used car transactions and serves as the key transportation hub in central China, providing strong fundamentals to support the operation of a large-scale used car superstore.

With the opening of the Zhengzhou superstore, Uxin is set to deliver a wider selection of high-quality vehicles and professional services to regional consumers, while significantly expanding its market penetration in central China. The continued rollout of new superstores is expected to be a key growth driver of Uxin's sales volume and financial performance in the coming years.

About Uxin
Uxin is China's leading used car retailer, pioneering industry transformation with advanced production, new retail experiences, and digital empowerment. We offer high-quality and value-for-money vehicles as well as superior after-sales services through a reliable, one-stop, and hassle-free transaction experience. Under our omni-channel strategy, we are able to leverage our pioneering online platform to serve customers nationwide and establish market leadership in selected regions through offline superstores with inventory capacities ranging from 2,000 to 8,000 vehicles. Leveraging our extensive industry data and continuous technology innovation throughout more than ten years of operation, we have established strong used car management and operation capabilities. We are committed to upholding our customer-centric approach and driving the healthy development of China's used car industry.

Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements. Statements that are not historical facts, including statements about Uxin's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk and uncertainties as to the timing of the entry into definitive agreements or consummation of the transactions; the risk that certain closing conditions of the transactions may not be satisfied on a timely basis, or at all; impact of the COVID-19 pandemic; Uxin's goal and strategies; its expansion plans and successful completion of certain financing transactions; its future business development, financial condition and results of operations; Uxin's expectations regarding demand for, and market acceptance of, its services; its ability to provide differentiated and superior customer experience, maintain and enhance customer trust in its platform, and assess and mitigate various risks, including credit; its expectations regarding maintaining and expanding its relationships with business partners, including financing partners; trends and competition in China's used car e-commerce industry; the laws and regulations relating to Uxin's industry; the general economic and business conditions; and assumptions underlying or related to any of the foregoing.

For investor and media enquiries, please contact:
Uxin Limited Investor Relations
Uxin Limited
Email: [email protected] 

The Blueshirt Group
Mr. Jack Wang
Phone: +86 166-0115-0429
Email: [email protected] 

SOURCE Uxin Limited

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Commerzbank share price has pulled back from its highest point this year as investors wait for more information from UniCredit. The CBK stock was trading at €32.7 on Friday, down from the year-to-date high of €38.3.

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) has struck a five-year supply agreement with a UK bus manufacturer that will see its driver monitoring technology installed on thousands of vehicles across Europe, ahead of the introduction of stricter safety rules.

The London-listed company, which develops artificial intelligence systems to track driver alertness, said its Guardian Generation 3 system will be fitted at the factory on new buses destined for European markets.

The tie-up builds on around 200 vehicles the bus maker has already fitted with the kit. The manufacturer produces more than 1,700 buses a year.

The move comes as the European Union prepares to enforce its General Safety Regulation. From July 2026, new buses, lorries and other heavy vehicles will need to include technology to detect driver distraction and warn of potential accidents.

Seeing Machines is also working with four other vehicle makers in Europe on regulatory approvals, known as homologation, that could cover more than 4,000 vehicles a year.

Homologation is the process by which a vehicle is certified to meet the required safety standards across an entire model range.

Beyond bus manufacturing, the company is advancing talks with a large oil and gas operator on a contract to expand Guardian across its European fleet. The system is already in use with this customer in the UK and four other European countries.

Paul McGlone, chief executive of Seeing Machines, said: “This agreement is a major step for Seeing Machines as we expand our Guardian Generation 3 technology across Europe, supporting our partners to meet the highest safety standards ahead of the GSR deadline.

"Our growing collaborations with OEMs and industry leaders not only demonstrate the value of our AI-powered safety technology but also reflect Europe's strong commitment to protecting road users.”

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).

If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:                                     

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Pennon Group PLC (LSE:PNN, OTC:PEGRY) has reported a strong start to its 2026 financial year, with profitability returning and EBITDA expected to increase by about 60% year on year. In a trading statement, the water utility company said it remains on track to deliver its 7% rate of return on equity (RORE) target, supported by efficient financing and programme efficiencies.

Chief executive Susan Davy said: "We're driving real improvements for our customers and communities whilst delivering a return to strong profitability. Despite the pressures of a hot summer, we've maintained resilient water supplies and continued to improve services for our customers. Whilst there is more to do, our pollution reduction plans are delivering tangible benefits, halving the number of pollutions and spills from storm overflows, reducing our impact on the environment."

The group highlighted that pollution incidents and storm overflow spills had halved year-on-year, supported by investments in wastewater networks and reduced rainfall. In water services, performance was impacted by supply interruptions from a burst main, although resources benefited from resilience measures put in place after the 2022 drought.

Pennon also strengthened its liquidity by raising £300 million under its Euro Medium Term Notes (EMTN) programme. Construction is progressing across Pennon Power's projects, with two sites in Scotland set to be connected to the Grid in October. When fully operational by FY27, the renewable energy portfolio will generate the equivalent of 40% of group consumption.

Following the planned retirement of Davy, the board has begun the search process for a new chief executive. Half-year results will be announced on 27 November 2025.

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo Purchase Licensing Rights, opens new tab

ZURICH, Sept 26 (Reuters) - Switzerland's Roche on Friday pointed to the fact that one of its U.S. units broke ground on a new facility in August and that the pharma company had pledged major U.S. investments after President Donald Trump's latest tariff announcement.

Trump said on Thursday the United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S.

Sign up here.

A Roche spokesperson pointed to the August 25 announcement about its Genentech unit's plans for the facility in Holly Springs, North Carolina as well as Roche's $50 billion pledge to invest in U.S. manufacturing and research and development.

Roche

(ROG.S), opens new tab and Novartis

(NOVN.S), opens new tab are Switzerland's two biggest pharmaceutical companies with major U.S. production operations. Novartis, which also made a large U.S. investment pledge earlier this year, did not immediately reply to a request for comment.

An industry source estimated that based on the initial U.S. indications, the tariffs as set out by Trump on Thursday would probably not apply to the two firms.

Reporting by Paul Arnold, Editing by Friederike Heine

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- Boeing [NYSE: BA] and Turkish Airlines announced today a firm order for up to 75 787 Dreamliners, the flag carrier's largest ever Boeing widebody purchase. The deal includes 35 of the 787-9 model, 15 of the larger 787-10, and options for 25 787 Dreamliners to grow and modernize the airline's fleet. The new order will support more than 123,000 jobs across the U.S.

Turkish Airlines orders up to 75 Boeing 787 Dreamliners, and commits to more 737 MAX jets.

The airline also announced its intent to purchase up to 150 more 737 MAX airplanes, which will be its largest Boeing single-aisle order when finalized. The 787 and 737 MAX orders combined will double Turkish Airlines' Boeing fleet as the carrier expands its capacity and network.

"This landmark agreement represents much more than a fleet growth. It is a reflection of our leadership in the industry as well as our dedication to innovation and operational excellence," said Prof. Ahmet Bolat, Turkish Airlines Chairman of the Board and the Executive Committee. "The addition of these advanced Boeing aircraft to our fleet will not only enhance our operational capabilities but also become a significant element supporting Turkish Airlines' 2033 Vision of expanding our fleet to 800 aircraft."

Across a network that reaches the most countries of any airline in the world, Turkish Airlines operates more than 200 Boeing jets today, including the 787-9, 777, 737 MAX, Next-Generation 737 and 777 Freighter airplanes.

Adding the larger 787-10 to its future fleet will enable Turkish Airlines to benefit from additional passenger and cargo capacity while improving fuel efficiency on high-demand routes between Istanbul and destinations in the U.S., Africa, Southeast Asia and the Middle East.

The 787-10, like the 787-9, also offers superior passenger comfort with the largest windows of any widebody jet, air that is less dry and pressurized at a lower cabin altitude, and technology that senses and counters turbulence for a smoother ride.

"We are honored that Turkish Airlines has once again chosen the 787 Dreamliner and 737 MAX to power its future growth," said Stephanie Pope, president and CEO of Boeing Commercial Airplanes.

Turkish Airlines is one of the global operators that have made the 787 a versatile component of their long-haul fleets. With more than 1,200 airplanes delivered, the 787 Dreamliner family serves about 500,000 passengers daily and connects the most countries of any widebody fleet.

Pope added, "As a proud partner to Türkiye and the Turkish aviation industry for 80 years, we look forward to continuing our support of Turkish Airlines as they expand operations and deliver exceptional experiences to their passengers."

For eight decades, Boeing has supported Türkiye's airline operators with commercial jets and services, as well as the government with defense platforms.

With offices in Ankara and Istanbul, Boeing has invested $2 billion in supply chain development, creating nearly 5,000 jobs in Türkiye. These investments foster growth in the local aerospace sector, promote innovation, and enhance the integration of Turkish industry into the global aerospace supply chain through its supplier development program.

A leading global aerospace company and top U.S. exporter, Boeing develops, manufactures and services commercial airplanes, defense products and space systems for customers in more than 150 countries. Our U.S. and global workforce and supplier base drive innovation, economic opportunity, sustainability and community impact. Boeing is committed to fostering a culture based on our core values of safety, quality and integrity.

Contact
Boeing Media Relations
[email protected]

SOURCE Boeing

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

AlphaTON has made its first buy of $30 million of Toncoin for its new treasury strategy. It comes shortly after the company closed a strong $71 million funding round for future TON purchases.

AlphaTON Commits $30M to Treasury Holdings
In a recent press release, AlphaTON,  a Nasdaq-listed firm dedicated to the Telegram ecosystem, confirmed that it has acquired approximately $30 million worth of TON following the close of $71 million in combined financing. The package included a $36.2 million private placement and a $35 million loan facility secured through BitGo Prime.

This purchase immediately positions the firm among the largest holders of the token globally. It also marked the company’s first major treasury transaction. The company also plans to expand its reserves to $100 million by the end of 2025. Additionally, this move would provide shareholders with institutional-grade exposure to Telegram’s billion-user ecosystem.

CEO Brittany Kaiser described the development as an opportunity for the company to invest in an infrastructure that will power decentralized applications across the Telegram network.

“Today marks a pivotal moment in AlphaTON Capital’s journey as we officially establish ourselves as a premier digital asset treasury company with substantial TON holdings,” she said. “These successful financings and immediate deployment…positions us to be a driving force in the next wave of decentralized application development”

This purchase comes shortly after the company launched its Toncoin treasury in the first week of the month. The firm rebranded from Portage Biotech to AlphaTON, aligning its corporate identity with its Toncoin-focused strategy. 

Enzo Villani, the company’s Executive Chairman and Chief Investment Officer, noted that the treasury initiative marks only the beginning of the company’s strategy. He clarified that by investing capital straight into the token, the company is positioned to take the lead in staking, validation, and ecosystem expansion as a whole.

Toncoin Treasury Momentum Builds
The firm’s move reflects a broader trend among treasury companies to increase their exposure to the token. In July, in collaboration with Kingsway Capital Partners, the TON Foundation launched a public vehicle dedicated to accumulating Toncoin, aiming to raise up to $400 million in funding.

Other firms are also following suit. Verb Technology, now known as TON Strategy, disclosed treasury assets worth $780 million earlier this year. This includes $713 million in the token alongside $67 million in cash reserves. The company approved a $250 million plan to buy back its own stock. This move aims to strengthen its balance sheet and create more value for shareholders.

These actions show that institutions are becoming more confident in the token’s ability to serve as a bridge between social media adoption and blockchain technology.

With AlphaTON’s financing round now complete, the firm outlined its growth strategy plans. The company plans to leverage its holdings for network validation and staking, generating predictable yield streams. They would also direct resources toward supporting decentralized applications built on the Telegram mini app ecosystem. 

It is also worth mentioning that the company is backed by stakeholders such as Animoca Brands, Kraken, SkyBridge Capital, and DWF Labs. The company has pledged to keep investors informed through regular treasury and operational updates in the months ahead.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

A cryptocurrency analyst has explained how a Chainlink triangle breakout setup could point to a massive $100 target for the asset’s price.

Chainlink Is Coiling Inside A Triangle Right Now
In a new post on X, analyst Ali Martinez has talked about a triangle pattern forming in the weekly price of Chainlink. Triangles refer to consolidation channels from technical analysis (TA) that involve an asset trading between two converging trendlines.

Like any other consolidation channel, the upper trendline acts a source of resistance, while the lower one that of support. In other words, tops can be likely to occur on retests of the former and bottoms at the latter.

There are a few different types of triangles, with some of the popular ones being the ascending, descending, and symmetrical variations. The orientation of the trendlines decides which type a particular triangle falls into.

Ascending and descending triangles have one trendline parallel to the time-axis: upper line in the former and lower one in the latter. Symmetrical triangles lie between the two, having both lines at a roughly equal and opposite slope.

Chainlink has potentially been trading inside a triangle over the last few years, but as the below chart shared by Martinez shows, this particular triangle doesn’t cleanly fit into any of these types.

Looks like the 1-week price of the coin has been trading near the upper boundary of the triangle | Source: @ali_charts on X
From the graph, it’s visible that Chainlink’s triangle lies is angled upward, but not fully, so it lies somewhere between a symmetrical triangle and an ascending one.

LINK made a retest of the upper line of the pattern earlier in the year and ended up finding rejection. The cryptocurrency is now on the way down, but the analyst thinks an extended drawdown may not actually be so bad.

“A dip to $16 on Chainlink $LINK would be a gift,” says Martinez. This price is where the 0.5 Fibonacci level lies. Fibonacci Extension/Retracement levels are lines drawn using ratios derived from the famous Fibonacci series.

The analyst has taken LINK’s top and bottom from the last few years as the 1 and 0 levels, respectively, and has drawn retracement levels between them. The $16 mark happens to be where one such key retracement level lies.

Martinez has highlighted in the chart what path the asset could end up following if it bounces off this level. It would appear that in the analyst’s view, a rebound from the line could end up leading to a breakout from the triangle and set a potential target at the 1.272 extension level, drawn up from the 1 level (top). In Chainlink price terms, this level corresponds to almost $100.

It now remains to be seen whether LINK will break out of the triangle in the near future, and whether a setup similar to the analyst’s would play out.

LINK Price
At the time of writing, Chainlink is floating around $20.25, down over 17% in the last seven days.

The price of the coin appears to have plummeted over the last few days | Source: LINKUSDT on TradingView
Featured image from Dall-E, charts from TradingView.com

Dogecoin price has crashed below an important level this week as liquidations jumped and the Crypto Fear and Greed Index sank into the fear zone. This article provides a DOGE price forecast as a risky pattern forms despite the ongoing DOJE ETF inflows.

TLDR:

AlphaTON Capital raised $71M through a share sale and credit facility to accelerate its TON-focused growth plan.
The company acquired $30M worth of TON tokens, becoming one of the largest holders in the Telegram ecosystem.
Leadership aims to scale TON treasury to $100M by Q4 2025 and expand network validation operations.
AlphaTON plans to invest in Telegram mini apps and DeFi projects to support ecosystem adoption.

Crypto investors now have another reason to watch the Telegram ecosystem closely. AlphaTON Capital has secured fresh funding and is stacking TON at scale. The company says its new position will let it shape the next wave of Telegram-based apps. 

Executives are betting big on TON’s future and plan to grow their holdings even more this year. This could set up a powerful play for treasury-backed growth in 2025.

According to a press release, AlphaTON Capital closed $71 million in financing through a mix of share sales and a $35 million credit line with BitGo Prime. The funds were immediately used to acquire $30 million worth of TON tokens, making AlphaTON one of the largest holders in the network.

The deal strengthens the company’s balance sheet and gives its investors direct exposure to the Telegram-linked blockchain. Executives say this first tranche sets the stage for a $100 million treasury goal by the end of 2025.

CEO Brittany Kaiser explained that the company is building more than just a reserve. She said their focus is on staking, validation, and seeding early Telegram mini apps that could reach millions of users.

Enzo Villani, Executive Chairman, said the financing positions AlphaTON at the intersection of social media and blockchain adoption. He expects staking operations to begin soon, generating predictable yield for the treasury.

TON Treasury Growth and Ecosystem Strategy
AlphaTON plans to scale its treasury through ongoing TON acquisitions and yield generation. The company says it will use validation rewards to reinvest in the ecosystem and back promising projects.

This includes scouting opportunities in Telegram mini apps, DeFi protocols, and infrastructure tools built on TON. The strategy is designed to capture value at multiple layers of the network.

The leadership team includes industry veterans from Nasdaq Global Corporate Solutions, SkyBridge Capital, and RSV Capital, which they say gives them a competitive edge in executing their growth plan.

The company expects to provide further updates on treasury expansion and early ecosystem investments in the coming months. Investors watching the TON price may look for signs of market reaction as AlphaTON grows its holdings.

The crypto market remains volatile. Bitcoin trades near $109,400, and Ethereum sits around $3,950. XRP is making headlines as it moves beyond its traditional role as a payment token and enters the broader DeFi ecosystem.

Axelar’s Interchain Token Service (ITS) now connects XRP to more than 80 blockchains. This allows XRP to operate across multiple networks and increases its utility. In September 2025, $mXRP, a staked version of XRP, launched with a 10% yield. The introduction of $mXRP has driven significant interchain activity. On-chain data shows that transfers via Axelar’s ITS reached approximately $6.6 million within a few days of the launch.

Record Interchain ActivityIn the second half of 2025, XRP led all tokens supported by Axelar in interchain transfers. It recorded 13,959 transactions, with a total transfer volume of nearly $23.3 million. This shows strong adoption and growing use of XRP beyond the XRP Ledger. The integration allows holders to earn yield and participate in DeFi opportunities without being directly affected by XRP’s price movements.

Reacting to the same, crypto lawyer Bill Morgan said, “Thanks for sharing. Haven’t seen this bullish data before.” 

Future OutlookGeorgios Vlachos, co-founder of Axelar, said the partnership allows new use cases, including tokenization and trading integrations. Midas, in collaboration with Interop Labs, created $mXRP as the first XRP-denominated yield product. The launch expands XRP’s functionality and strengthens Axelar’s role in the multi-chain ecosystem.

Analysts see this as a step forward for XRP. By combining staking rewards, interchain transfers, and access to over 80 blockchains, XRP can become a key player in the DeFi space. The partnership also benefits Axelar by increasing its visibility and presence across multiple networks.

The past day wasn’t kind to the cryptocurrency markets, as bitcoin slumped below a crucial support level and dipped to a three-week low of under $109,000 yesterday.

Most altcoins crashed even harder, which is why the leveraged liquidations have skyrocketed to nearly $1 billion, according to CoinGlass.

BTCUSD. Source: TradingView
It was less than a week ago when the primary cryptocurrency stood tall at $118,000 after the US Federal Reserve cut the interest rates for the first time this year. However, the asset failed to maintain its run and started to lose value rapidly.

Harrowing trading days were Monday (September 22) and Thursday (September 25). At first, BTC dumped from $115,500 to $112,000. It managed to recover some ground mid-week, but the bears initiated another leg down yesterday, which drove bitcoin further south to its lowest position since the start of the month at $108,600 (on Bitstamp).

Although it has recovered around a grand since then, BTC is still below $110,000, which is a crucial support level, according to Ali Martinez. The next one actually managed to hold the freefalls, which is set at $108,530.

As usual, many industry observers and commentators began speculating on the state of the correction. Some, such as Peter Schiff, called it the start of a bear market.

Crypto analysts remain more optimistic. Captain Fabrik, for instance, referred to the current retracement as a ‘healthy’ one and predicted a surge to $140,000 as long as BTC can reclaim the $113,000 resistance.

Nevertheless, almost all altcoins followed bitcoin on the way south, posting massive losses. Ethereum is among the poorest performers as it lost the $4,000 support and slumped beneath $3,900 yesterday. XRP is deep in the red as well, dumping by 10% weekly and struggling to remain close to $2.80.

This enhanced volatility has harmed over-leveraged traders, as the total value of wrecked positions has shot up to almost $1 billion on a daily scale. More than 225,000 such market participants have been liquidated daily.

Liquidation Heat Map. Source: CoinGlass

Crypto mining company TeraWulf is reportedly raising approximately $3 billion through Morgan Stanley to build data centers, with tech giant Google providing support.

The TeraWulf funding round will support the build-out of its data centers with a structure supported by Google, according to company finance chief Patrick Fleury, who spoke to Bloomberg on Thursday.

Deal could launch as soon as October in high-yield bond or leveraged loan markets. Google’s backstop commitment to support the debt financing is an additional $1.4 billion, bringing its total to $3.2 billion.

The Google support could give the Morgan Stanley transaction a higher rating from credit rating firms. However, the terms of the transaction are still under negotiation, and there is no guarantee a deal will launch, Bloomberg said. 

The AI boom has created severe shortages of data center space, GPU chips, and reliable electricity access, and large crypto mining companies are well-positioned because they already possess the two scarcest resources, existing data center infrastructure and secured power capacity. 

Fluidstack agreement backed by GoogleIn August, TeraWulf announced a ten-year colocation lease agreement with Fluidstack, an AI infrastructure provider.

The deal, worth $3.7 billion in contract revenue, was also backstopped by Google, which took a 14% stake in TeraWulf. 

Google has now committed $3.2 billion across both deals, showing serious long-term investment in crypto-to-AI infrastructure conversion.

Cointelegraph reached out to Terawulf for further details, but did not receive an immediate response. 

TeraWulf stock spikesTeraWulf stock (WULF) spiked 12% on Thursday, hitting an intraday high of $11.72 before it retreated to end up down 3.7% on the day at $10.97 in after-hours trading, according to Google Finance. 

Company shares surged after the initial announcement in August, jumping 80% in the days that followed. TeraWulf has had a solid year with share prices up 94% since the beginning of 2025. 

TeraWulf stock has surged since its initial agreement. Source: Google FinanceCipher Mining signs similar dealCipher Mining announced a very similar agreement on Thursday, partnering with the same AI cloud firm Fluidstack and being backed by Google, which took a 5.4% stake in the company.

Cipher will provide data-center capacity for Fluidstack under a colocation agreement, while Google will obtain an equity stake in Cipher and backstop $1.4 billion of the obligations. 

Magazine: ‘Help! My robot vac is stealing my Bitcoin’: When smart devices attack

Bitcoin, the pioneer cryptocurrency, has slipped to a four-week low, trading under $109,500, leaving many traders anxious about its next move. But veteran analyst Timothy Peterson believes the drop could just be part of a bigger setup. 

Using Bitcoin’s 10-year seasonality trends, he suggests the BTC to climb as high as $200,000 by June 2026, and even higher if seasonality repeats.

In his analysis, Peterson highlighted Bitcoin’s 10-year seasonality chart, which tracks the asset’s typical behavior over the course of a year. Instead of looking at the calendar year, he shifted the timeline by six months to better capture Bitcoin’s bull cycles.

According to his research, Bitcoin’s strongest performance window runs from October 11 to June 11. Historically, this period has produced the steepest gains in Bitcoin’s cycle.

If history repeats itself, Bitcoin could climb at an average pace of 7% per month, which works out to around 120% yearly gains.

Bitcoin Price PredictionAccording to analyst Peterson, Bitcoin now has a 50% or higher chance of reaching $200,000 by June 2026. That would mean the price would nearly double from current levels in less than a year.

In a stronger rally, the move could stretch even further, with Bitcoin potentially climbing toward $240,000 later in the cycle.

Peterson also highlighted early November as a key period to watch, since Bitcoin has a history of breaking into new all-time highs around that time. Therefore, Peterson suggests that a more cautious move could see Bitcoin climb toward $160,000 as the first major milestone. 

BTC Price Forecast – Short TermAs of now, Bitcoin price is trading at $109,422, down 3% in the past 24 hours, erasing billions from the market.  Meanwhile, a key factor that analysts are watching closely is the Short-Term Holder (STH) Cost Basis, currently at $111,500. 

This level is increasingly seen as a critical line between bullish and bearish market behavior. Thus, the immediate support lies at $108,600, with stronger support near $108,000. 

A break below these levels may accelerate the downturn, potentially dragging Bitcoin toward the $105,000 zone, which could spark a wider market panic.

Crypto prices continued to crater Thursday, with Bitcoin dropping below the $110,000 psychological mark, Ethereum (ETH) sinking below $4,000 for the first time since early August, and assets like XRP falling 6.1% as investors, fretful about macro and geopolitical factors, shied away from cryptocurrencies and other risk-on assets.

Bitcoin Price Crumbles Under $110,000 Amid Macro Jitters
Bitcoin (BTC), the industry’s largest crypto, which has already been trading weakly over the past few days, plummeted below $110,000 to its lowest price since early September before reversing to $109,490, down 3.5% over the past 24 hours.

Ethereum has taken a much harder hit on the day. Data from CoinGecko shows that the second-largest cryptocurrency by market cap traded hands at $3,905 as of publication time, down 15% from seven days ago.

While the U.S. Federal Reserve lowered interest rates in September, the 25 basis point rate cut failed to trigger a parabolic bull surge as once anticipated. One of the factors was Chairman Jerome Powell’s comments, which tapered expectations for the Fed to slash interest rates further next month.

Another notable headwind for Ether is the reduced inflows for spot ETH exchange-traded funds (ETFs) this month, signaling weaker institutional demand that could push the price lower. So far in September, the ETH funds have collectively pulled in a mere $110 million, while August’s net inflows surpassed $3.7 billion.

Advertisement
 

Major altcoins like XRP have also plunged, with the Ripple-promoted asset sliding as much as 5.1% on the day to a price of $2.80. Dogecoin remains the biggest loser in the top 10 coins. The OG meme coin and eighth-largest cryptocurrency was trading close to $0.2287.

Over $1 Billion In Bullish Bets Get Rekt
Amid Thursday’s carnage, liquidations have only accelerated across the crypto market with CoinGlass data showing $1.14 billion worth of “rekt” positions over the last 24 hours. Ethereum is leading the charge there with about $434 million worth, followed by Bitcoin at $276 million.

The vast majority of the liquidations are longs — or bets that an asset’s price will soar — at $1.04 billion worth.

Meanwhile, sentiment in the industry remains poor, with the Crypto Fear and Greed Index slipping to ‘fear’, reaching a score of 44.

Datavault AI Inc. (NASDAQ: DVLT) shares ripped higher in Thursday's after-hours trading after securing $150 million investment in Bitcoin (CRYPTO: BTC) to build a supercomputer. 

DVLT is surging to new heights today. Check the fundamentals here.

‘Strategic’ Investment To Boost InfrastructureThe stock rallied over 23% in the after-hours session, building on its gains from the regular trading session. Shares of the data sciences technology firm jumped to an intraday high of $1.07, marking a 64% jump from the previous close.

The surge comes after biotech firm Scilex Holding Company (NASDAQ: DVLT) made a “strategic investment” of $150 million, intending to boost Datavault’s supercomputing infrastructure, expand independent data exchanges and open new revenue streams.

The transaction was executed in Bitcoin at the spot exchange rate. Scilex Holdings’ investment aims to capture growth in the growing biotech data monetization market.

See Also: Top Stock Movers Today | Top Stock Gainers & Top Stock Losers

Price Action: At the time of writing, BTC was exchanging hands at $109,715, down 2.62% over the last 24 hours, according to data from Benzinga Pro.

Datavault AI shares rallied 23.38% in after-hours trading after closing +28.43% higher at $0.8348 during Thursday’s regular trading session.

Scilex Holding stock fell 2.16% after-hours, despite closing 1.92% higher at $29.14 earlier.

The stock lagged on the Momentum and Growth parameters. How does it compare with Coinbase Global Inc. COIN and other cryptocurrency-linked stocks? Visit Benzinga Edge Stock Rankings to find out.

Read Next: 

What’s Going On With Intel Stock Today?
Image via Shutterstock/ Zakharchuk

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Journalist

Posted: September 26, 2025

Key Takeaways
Why is SUI still in focus despite lagging L1 peers?
SUIG has stacked 101 million SUI and added 19 million in the last 30 days, nearly 27× faster than ETH accumulation.

How is SUI proving its value on-chain?
The network sees 4.5 million daily transactions and 927k daily active addresses, almost 3× Ethereum’s.

Sui [SUI] is clearly lagging its L1 peers.

Most big-cap L1s have bounced back from the Q1–Q2 bloodbath, riding a solid Q3, but SUI is still 40% off its Q1 highs. Meanwhile, Ethereum [ETH] has recovered 100% of its H1 losses with a 60%+ Q3 pump.

No doubt, ETH’s rally got a boost from institutions, with BitMine [NASDAQ: BMNR] holding 2.4 million ETH. On the SUI side, SUI Group Holdings (NASDAQ: SUIG) has stacked 101 million SUI, totaling 2.8% of the supply.

Source: CoinGecko

In short, institutional appetite is there, but SUI’s still playing catch-up.

Reinforcing this, on-chain, SUIG has been on a tear, grabbing 19 million SUI in the past 30 days, while BMNR only added 702k ETH. That’s nearly 27× faster accumulation, showing SUIG is loading up at a crazy pace.

In fact, SUIG recently repurchased 276k shares under its new $50 million stock buyback program. Could this be a signal of deeper confidence in SUI, which, compared to other high-cap L1s, still looks undervalued?

SUI’s slow and steady grind is building real adoption
A 276k share buyback shows SUIG is trying to juice its stock price.

Q3 hasn’t been kind. SUIG is down 32% from its $5.37 open, showing the market demand isn’t really there. In this context, the $50 million buyback is basically a move to support the float and add value for shareholders.

On top of that, it’s also pumping liquidity into their 101 million SUI stack, keeping institutional bags safe. Meanwhile, SUI’s daily active addresses just hit a monthly high of 927k.

Source: Artemis Terminal

By contrast, Ethereum’s DAA remains flat at 530k.

On-chain, SUI’s adoption is clearly stacking up. The network processes 4.5 million daily transactions, almost 3x that of Ethereum, showing users are actually using SUI for real on-chain activity, not just holding.

Coupled with deeper institutional appetite and the network’s genuine on-chain engagement, SUI’s undervaluation thesis is looking stronger, positioning it as a key pillar in the Web3 transformation.

Ritika Gupta is a Financial Journalist and Geopolitical Analyst at AMBCrypto, specializing in the critical intersection of world politics, economic policy, and the cryptocurrency markets. Her analysis is informed by her distinguished background, which includes professional experience at major news network.
She holds a Bachelor's degree in Political Science and Psychology from Gargi College, University of Delhi. This academic training provides her with a sophisticated framework for dissecting complex issues such as international regulations, government fiscal policies, and the geopolitical forces that directly influence asset valuations.
At AMBCrypto, Ritika applies this expert lens to synthesize macroeconomic data and political developments, offering readers a deeper context for market movements. She excels at explaining not just what is happening in the market, but why it is happening. Her work is dedicated to providing strategic insights that empower readers to understand the complex relationship between global events and their digital assets.